Study of Phage Therapy Plus Antibiotics to Treat Infective Endocarditis in Adults

What this Trial Is About

Infective endocarditis IE is a serious infection affecting the heart valves or endocardium, often caused by bacteria or fungi, with increasing cases mainly in high-income countries. The disease can be complicated and life-threatening, including risks during hospital treatment and afterward. Antibiotic resistance is a growing challenge in treating IE, prompting the need for new therapies like bacteriophage phage therapy, which uses viruses that specifically attack bacteria. This trial evaluates phage therapy combined with standard antibiotics compared to a placebo plus antibiotics in patients with IE. Participants receive either a bacteriophage cocktail targeting common bacteria causing IE or a placebo while continuing standard antibiotic treatment. The treatment is given early in the disease to help control infection and reduce resistance risks, potentially allowing earlier transition to outpatient care. Participants will be monitored for up to 8 weeks, with researchers tracking hospital stay length, embolic events, and survival rates. The study involves clinical evaluations, microbiological tests, and safety monitoring to assess how well the combined treatment controls infection. The trial is randomized and placebo-controlled to compare the effects of phage therapy alongside antibiotics in patients hospitalized with active IE.

Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis